Announcement
Announcement under Regulation 30 (LODR)-Newspaper Publication 25 Aug - The Newspaper Publication regarding the extension of the Special Window for Re-Lodgement of Transfer Request of Physical Shares.
Source: Bse
Bliss GVS Pharma Limited (BLISSGVS)
Small CapPharma stocks · Small cap · NSE
Bliss GVS Pharma Limited operates in Formulations, within the Pharma sector. Use the latest filing and company disclosures below to verify its revenue mix and current business drivers.
Data qualityFresh enough for analysisQuote updated 19 Oct, 03:31 pm ISTDetails
Quote19 Oct, 03:31 pm IST
Base fundamentals06 Oct 2026 · screener
Latest result12 Aug, 07:54 pm IST
Score20 Oct, 04:30 am IST · v4.3-runtime-valuation
Tags02 May 2026
Coverage14/14 · 100%
Valuation2026-07-20 · Rf 6.8% · Pharma P/E 33.5 (n=187)
Technical timing lens
Trend score and candlestick chart
76BullishSMA20 +5.1% / mo · MACD − · sector +3.8pp vs Nifty 500 (3M)
Stock trend: 61
Sector RS: 98
Sector 3M: -1.8% vs Nifty 500 -5.6%
Pharma FPI tailwindFlow only
FPI equity flow was positive in both fortnights, but the sector index is below its 100-session average. View sector evidence
Technical chart
BLISSGVSD candles · FIT view+138.7%Latest close ₹627.05 on 2026-10-19
Bar
-5.4%
RSI
41
MACD hist
-9.73
52W pos
82%
2026-10-19O ₹662.50H ₹662.50L ₹620.00C ₹627.05Vol 1.2L sh
Up bar
Down bar
EMA 20
EMA 50
Volume + 20D avg
Result date
RSI(14)
MACD / signal
Market context
Relative performance and chart statistics
Adjusted completed-session prices, rebased to 100
BLISSGVSNifty PharmaNifty 500
- BLISSGVS
- +29.9%
- Nifty 500
- -5.6%
- Nifty Pharma
- -1.5%
- Vs Nifty 500
- +35.5 pp
Chart stats
19 Oct 2026- From 52W high
- -15.3%
- 52W range position
- 82%
- ATR (14)
- 4.9%
- Volume vs 20D
- 0.36x
- Avg traded value
- ₹23.1 Cr
- 20D price channel
- ₹620 - ₹739.9
₹739.9
₹118 - ₹739.9
₹30.8
Latest completed session
20-session average
40.5% annualized volatility
Research snapshot
What the evidence says now
Weak fundamentals, while price trend supports entry. This looks more like momentum/speculation than a clean fundamental investment setup.
Weak U-Score but strong trend: momentum may be ahead of fundamentals.
Suggested next step
Momentum only
Trend is strong but fundamentals do not support a clean investment thesis.
U-Score
Legacy · WATCHLIST39
Fundamental lens: valuation, quality, growth, balance sheet, and cash flow.
Latest result
Excellent75
Revenue +38.2% · PAT +15.9% YoY
Technical
Bullish76
Price trend and sector-relative-strength timing.
Valuation
Legacy model-8.4%
Legacy margin-of-safety estimate; the revised evidence label remains in shadow validation.
Trust
Limited evidence79
Financial-only signal; management claim evidence is not sufficient yet.
Financials
Fundamentals, quarterly history, margins, returns and balance-sheet evidence
Financials
Fundamentals, quarterly history, margins, returns and balance-sheet evidence
Latest result
Quarter ended 30 Jun 2026
Excellent · 75/100Rev +38% YoY · PAT +16% YoY · margin expansion · +11% QoQ
Filed 12 Aug 2026
Open results browser →| Metric | This quarter | YoY | QoQ |
|---|---|---|---|
| Revenue | ₹286 Cr | +38.2% | +11.3% |
| EBITDA | ₹76 Cr | +85.4% | +72.7% |
| Operating margin | 27.0% | +700 bps | +1000 bps |
| PAT | ₹51 Cr | +15.9% | +37.8% |
| PAT margin | 17.8% | -343 bps | +343 bps |
NDF means not disclosed in the current structured filing feed. It is intentionally not treated as zero.
Fundamentals
Valuation
- P/E
- 51.40
- P/B
- 5.88
- EV/EBITDA
- 30.30
- Market Cap
- 7069.00Cr
Profitability
- ROE
- 11.80%
- ROCE
- 16.90%
- ROA
- 9.52%
- Dividend Y
- 0.23%
Growth (CAGR)
- Revenue 5Y
- 10.00%
- EPS 5Y
- 14.00%
- Revenue 3Y
- 7.00%
- EPS 3Y
- 23.00%
Balance Sheet
- Debt/Equity
- 0.02
- Interest Coverage
- 28.43×
- Altman Z
- 8.51
- Book Value
- 113.00
Cash Flow
- FCF Yield
- 1.43%
- FCF Positive Y
- 11/5
- OCF
- 139.00 Cr
- EPS TTM
- 12.86
Shareholding
- Promoter Hold
- 26.00%
- Promoter Pledge
- 0.00%
- Momentum 52W
- 87%
Financial History
Updated 20/10/2026
Revenue
₹ CrLatest: 286+11.3% vs prev
Net Profit
₹ CrLatest: 51.0+37.8% vs prev
ROE is shown only in the Annual view — quarterly equity data isn't published.
Technicals
Trend interpretation, Stage 2, relative strength, volume and indicator evidence
Technicals
Trend interpretation, Stage 2, relative strength, volume and indicator evidence
Daily technical trend read
Mixed signalsSignals are conflicting — long-term uptrend intact. RSI 41. Wait for confirmation.
- Price above SMA200 (long-term uptrend) but mid-term MAs not aligned.
- SMA20 rising (~4.9% over last month) — short-term momentum positive.
- RSI(14) at 41 — falling, no extreme reading.
- MACD below signal, histogram expanding negatively — bearish momentum building.
- 15% off 52W high · 431% above 52W low.
Mechanical read from the price + indicator series above. Not a recommendation — technical setups can reverse without warning, especially around earnings and macro events.
Nifty 500 leadership
Relative Strength & Trend Stage
98
RS percentile
Stage 2 UptrendEstablished S2
1M return
-8.0%
3M return
+29.9%
6M return
+129.2%
1Y return
+312.4%
RS 1D
0
RS 20D
-1
Sector rank
#1
Industry rank
#11
Stage evidence
- Price is 36.9% above the 30-week proxy.
- The 50-DMA is above the 30-week proxy and its slope is rising +15.6%.
- Both 3-month and 6-month returns are positive.
50-DMA
price below
200-DMA
price above
S2 entered
27 Jan 2026
S2 age
188 trading sessions
Sector
leading
Industry
leading
Relative-strength line vs Nifty 500 (base 100)
262 observations
19 Oct 2026Value 446.27-2.83%
RS vs Nifty 500446
Valuation & peers
U-Score 39 · legacy U-Score band WATCHLIST · valuation evidence and comparable companies
Valuation & peers
U-Score 39 · legacy U-Score band WATCHLIST · valuation evidence and comparable companies
WATCHLIST
Fundamental score breakdown
U band · WATCHLISTValuation0/30
Growth13/25
Quality6/20
Balance Sheet9/15
Cash Flow7/10
Piotroski
8/9 (+5)
Penalties
-1
Raw sum
39
Why this score?
Top U-Score contributors and drags from the latest stored fundamentals.
39/100 · legacy band WATCHLIST
Positive drivers
- Piotroski is strong at 8/9.
- Cash flow contributes 7/10 to the score.
- Balance sheet contributes 9/15 to the score.
Main drags
- Penalty bucket subtracts 1 points.
- Fair-value margin of safety is negative at -8.4%.
- Valuation is weaker at 0/30; verify the latest quarterly trend.
Sector valuation model
Healthcare valuation: PE/EVEBITDA with regulatory and pipeline checks
Healthcare valuation needs both earnings quality and regulatory/pipeline context.
Primary lens
PE and EV/EBITDA adjusted for product mix and R&D/pipeline quality.
Secondary checks
USFDA risk, launch pipeline, margin trend, domestic vs export mix.
Main risk check
Regulatory setbacks or one-off product cycles can distort valuation.
PE
51.4
PB
5.9
EV/EBITDA
30.3
ROE
11.8%
ROCE
16.9%
FCF Yield
1.4%
Debt/Equity
0.0
MoS
-8.4%
Score movement
Stored run vs live recompute
This shows the stored score trend when snapshots exist, and also compares the latest stored nightly score with a live recompute from current fundamentals and price.
Stored run: 20 Oct 2026
v4.3-runtime-valuation
Final score
39
Previous: 39
Legacy U-Score band
WATCHLIST
Previous: WATCHLIST
Margin of safety
-8.4%
Previous: -8.4%
Score history
12 stored score snapshots. Latest stored move: +0 points.
20 Oct 2026
v4.3-runtime-valuation
39
39
39
39
39
39
39
39
39
39
39
39
Factor attribution
No pillar movement versus the latest stored run. Historical score trend will appear after snapshot storage is enabled.
Modelled fair value
Graham Number
₹180.82
-246.8% MoS
Growth-justified P/E
45.0
Growth-justified Value
₹578.7
-8.4% MoS
PEG
2.92
Comparable companies
Peers
Business-comparable peers in Pharma — ranked by industry, sub-sector, theme-tag overlap, market cap, and U-Score similarity. Green cells mark the best available peer metric in this table.
Ticker
Name
Why peer
Score
PE
ROE
MoS
Verdict
SANOFI
Small
Sanofi India Limited
Pharmaceuticals
match 167
53
15.8
47.1%
-305%
FAIR VALUE
INNOVACAP
Small
Innova Captab Limited
Pharmaceuticals
match 167
48
42.6
13.7%
+17%
FAIR VALUE
FDC
Small
FDC Limited
Pharmaceuticals
match 166
40
17.5
11.2%
-180%
WATCHLIST
NOVARTIND
Small
Novartis India Limited
Pharmaceuticals
match 165
40
49.7
11.6%
-8%
WATCHLIST
ZOTA
Small
Zota Health Care LImited
Pharmaceuticals
match 163
26
—
-15.0%
—
OVERVALUED
Business, management & trust
Growth engines, risks, management commitments and evidence-backed delivery
Business, management & trust
Growth engines, risks, management commitments and evidence-backed delivery
Business and thesis
Issuer presentation review pending
Bliss GVS Pharma Limited operates in Formulations, within the Pharma sector. Use the latest filing and company disclosures below to verify its revenue mix and current business drivers. The structured result feed currently covers the quarter ended 30 Jun 2026. Investor presentations and earnings-call PDFs will be added as issuer-backed evidence before management claims appear here.
Trust Score
79Limited evidence · low confidenceTrust Lite
Trust asks: does management behaviour match later outcomes? Higher is better, but confidence and evidence depth matter as much as the number.
Limited evidence: Claim history is still being built. It ranks around the 88th percentile of the scored universe and 83rd percentile within Pharma. No major sub-score weakness stands out.
This is a financial-behaviour screen, not a claim-tested management reliability verdict.
Computed 05 Sept 2026
management-trust-v1
24 docs text-extracted · 0 concalls text-extracted
Score band
Limited evidence
Financial behaviour is scored, but management claims do not yet have enough outcome checks.
Relative rank
88th percentile
overall median 67 · Pharma: 83rd pctile, median 70 · Small: 90th pctile, median 66
Evidence depth
Financial-only
24 documents have extracted text, but claim history is not strong enough yet.
Claim delivery
Outcome history still building
0 claims extracted · No contradicted claim yet
How to read this Trust Score
Limited evidence · low confidenceWhat it measures
Reliability of management and financial delivery, using financial behaviour only.
Confidence
Treat this as an early read until more concalls and outcomes are matched.
Investor use
Can support position sizing if valuation and trend also agree.
Read Trust alongside U-Score, result consistency, and technical trend. A cheap stock with weak Trust needs a larger margin of safety; a high Trust score does not make an expensive stock attractive by itself.
Forensic breakdown
Read low sub-scores as due-diligence warnings, not automatic sell signals.
Promoter
82
strong · holding, pledge, alignment
Cash flow
77
strong · profit to cash conversion
Balance sheet
96
strong · leverage and solvency
Discipline
68
acceptable · capital discipline
Results
69
acceptable · quarterly consistency
Trust positives
- ▸Promoter pledge is zero.
- ▸Promoter holding increased 25%.
- ▸FCF yield is positive at 1.4%.
- ▸11 years of positive FCF.
Trust risks
- ▸OPM spread across recent quarters is 16%.
Trust Lite uses financial behaviour only. Prefer claim-tested Trust when enough concall claims have later outcomes.
Continue researching Bliss GVS Pharma Limited
Important announcements & filings
Latest exchange and company disclosures found within the past two years.
Open source ↗
Announcement
Announcement under Regulation 30 (LODR)-Newspaper Publication 21 Aug - The Newspaper Publication regarding the publication of the advertisement for the Postal Ballot Notice.
Source: Bse
Announcement
Announcement under Regulation 30 (LODR)-Newspaper Publication 14 Aug - The copies of newspaper advertisement published regarding the extract of statement of Un-audited Standalone and Consolidated Financial Results of the Company ....
Source: Bse
Annual report
Annual Report 2026
Source: Bse
Annual report
Annual Report 2025
Source: Bse
All information is for study purposes only. For investment decisions, consult your financial advisor. See Playbook for methodology.